Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up $0.20 on Tuesday, reaching $73.29. The company’s stock had a trading volume of 8,387,977 shares, compared to its average volume of 9,229,104. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The firm has a market cap of $96,250.00, a PE ratio of 7.86, a PEG ratio of -1.26 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences’s payout ratio is presently 23.66%.

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Keel Point LLC grew its position in shares of Gilead Sciences by 0.4% in the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares during the last quarter. Paradigm Financial Advisors LLC grew its position in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 26 shares during the last quarter. West Oak Capital LLC grew its position in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 32 shares during the last quarter. First Heartland Consultants Inc. grew its position in shares of Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC grew its position in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 41 shares during the last quarter. 76.23% of the stock is owned by institutional investors and hedge funds.

GILD has been the subject of several recent research reports. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Berenberg Bank restated a “buy” rating and issued a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a research note on Monday, August 28th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Finally, Credit Suisse Group set a $79.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $85.22.

ILLEGAL ACTIVITY WARNING: “John C. Martin Sells 73,333 Shares of Gilead Sciences, Inc. (GILD) Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/05/john-c-martin-sells-73333-shares-of-gilead-sciences-inc-gild-stock.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.